The ‘biosimilar challenge’ (or ‘bio battle’) is one of the most significant commercial changes we have seen in the pharma industry.

Adelphi has applied expertise and knowledge from recent research conducted around biosimilars to assess the overall impact on patients, payers and physicians alongside the commercial implications for pharma.

Download the full article by Rachel Medcalf - Managing Director, Adelphi Research UK